The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study
Open accessAbstract
Background Various observations have suggested that the course of COVID-19 might be less favourable in patients with inflammatory rheumatic and musculoskeletal diseases receiving rituximab compared with those not receiving rituximab. We aimed to investigate whether treatment with rituximab is associated with severe COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases. Methods In this cohort study, we analysed data from the French RMD COVID-19 cohort, which included patients aged 18 years or older with inflammatory rheumatic and musculoskeletal diseases and highly suspected or confirmed COVID-19. The primary endpoint was the severity of COVID-19 in patients treated with rituximab (rituximab group) compared with patients who did not receive rituximab (no rituximab group). Severe disease was defined as that requiring admission to an intensive care unit or leading to death. Secondary objectives were to analyse deaths and duration of hospital stay. The inverse probability of treatment weighting propensity score method was used to adjust for potential confounding factors (age, sex, arterial hypertension, diabetes, smoking status, body-mass index, interstitial lung disease, cardiovascular diseases, cancer, corticosteroid use, chronic renal failure, and the underlying disease [rheumatoid arthritis vs others]). Odds ratios and hazard ratios and their 95% CIs were calculated as effect size, by dividing the two population mean differences by their SD. This study is registered with ClinicalTrials.gov, NCT04353609. Findings Between April 15, 2020, and Nov 20, 2020, data were collected for 1090 patients (mean age 55·2 years [SD 16·4]); 734 (67%) were female and 356 (33%) were male. Of the 1090 patients, 137 (13%) developed severe COVID-19 and 89 (8%) died. After adjusting for potential confounding factors, severe disease was observed more frequently (effect size 3·26, 95% CI 1·66–6·40, p=0·0006) and the duration of hospital stay was markedly longer (0·62, 0·46–0·85, p=0·0024) in the 63 patients in the rituximab group than in the 1027 patients in the no rituximab group. 13 (21%) of 63 patients in the rituximab group died compared with 76 (7%) of 1027 patients in the no rituximab group, but the adjusted risk of death was not significantly increased in the rituximab group (effect size 1·32, 95% CI 0·55–3·19, p=0·53). Interpretation Rituximab therapy is associated with more severe COVID-19. Rituximab will have to be prescribed with particular caution in patients with inflammatory rheumatic and musculoskeletal diseases. Funding None.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
mice: Multivariate Imputation by Chained Equations in R
Buuren, S. V., & Groothuis-Oudshoorn, K. (2011) · Journal of Statistical Software · doi:10.18637/jss.v045.i03 · Cited by 13,870
Austin, P. C. (2009) · Statistics in Medicine · doi:10.1002/sim.3697 · Cited by 6,758
Virological assessment of hospitalized patients with COVID-2019
Wölfel, R., Corman, V. M., Guggemos, W., Seilmaier, M., Zange, S., Müller, M. A., Niemeyer, D., Jones, T. C., Vollmar, P., Rothe, C., et al. (2020) · Nature · doi:10.1038/s41586-020-2196-x · Cited by 6,661
(2010) · University of Twente Research Information · Cited by 6,037
Austin, P. C., & Stuart, E. A. (2015) · Statistics in Medicine · doi:10.1002/sim.6607 · Cited by 4,495
Austin, P. C. (2011) · Pharmaceutical Statistics · doi:10.1002/pst.433 · Cited by 3,949
To, K. K.-W., Tsang, O. T.-Y., Leung, W.-S., Tam, A. R., Wu, T.-C., Lung, D. C., Yip, C. C.-Y., Cai, J.-P., Chan, J. M.-C., Chik, T. S.-H., et al. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30196-1 · Cited by 3,066
Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients
Hadjadj, J., Yatim, N., Barnabei, L., Corneau, A., Boussier, J., Smith, N., Péré, H., Charbit, B., Bondet, V., Chenevier-Gobeaux, C., et al. (2020) · Science · doi:10.1126/science.abc6027 · Cited by 2,984
Mathew, D., Giles, J. R., Baxter, A. E., Oldridge, D. A., Greenplate, A. R., Wu, J. E., Alanio, C., Kuri-Cervantes, L., Pampena, M. B., D’Andrea, K., et al. (2020) · Science · doi:10.1126/science.abc8511 · Cited by 1,509
Strangfeld, A., Schäfer, M., Gianfrancesco, M. A., Lawson-Tovey, S., Liew, J. W., Ljung, L., Mateus, E. F., Richez, C., Santos, M. J., Schmajuk, G., et al. (2021) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2020-219498 · Cited by 667
Self-citation
Cited by
Apostolidis, S. A., Kakara, M., Painter, M. M., Goel, R. R., Mathew, D., Lenzi, K., Rezk, A., Patterson, K. R., Espinoza, D. A., Kadri, J. C., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01507-2 · Cited by 507
Maher, T. M., Tudor, V. A., Saunders, P., Gibbons, M. A., Fletcher, S. V., Denton, C. P., Hoyles, R. K., Parfrey, H., Renzoni, E. A., Kokosi, M., et al. (2023) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(22)00359-9 · Cited by 290
Sparks, J. A., Wallace, Z. S., Seet, A. M., Gianfrancesco, M. A., Izadi, Z., Hyrich, K. L., Strangfeld, A., Gossec, L., Carmona, L., Mateus, E. F., et al. (2021) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2021-220418 · Cited by 238
Self-citation
Metadata
- Authors
- Avouac, J., Drumez, E., Hachulla, E., Seror, R., Georgin-Lavialle, S., El Mahou, S., Pertuiset, E., Pham, T., Marotte, H., Servettaz, A., Domont, F., Chazerain, P., Devaux, M., Claudepierre, P., Langlois, V., Mekinian, A., Maria, A. T. J., Banneville, B., Fautrel, B., Pouchot, J., Thomas, T., Flipo, R.-M., Richez, C., Aeschlimann, F., Agard, C., Ait-Abdallah, N., Albert, J.-D., Alcais, D., Allain, J.-S., Allanore, Y., Amador-Borreiro, B., Amoura, Z., Andre, E., Arbault, A., Arlet, J.-B., Arnaud, L., Arniaud, D., Arty-Hue, H., Atlan, L., Audemard-Verger, A., Audoin-Pajot, C., Audren, V., Bach-Bunner, M., Bacquet-Deschryver, H., Bader-Meunier, B., Balandraud, N., Balblanc, J.-C., Bally, S., Banal, F., Barbery, P., Barnetche, T., Barrelet, A., Basch, A., Baumier, V., Bayer, G., Bayle, S., Beauvais, C., Beinat, R., Belin, V., Belkhir, R., Benainous, R., Belot, A., Benammar, M., Benhamou, M., Benhamou, Y., Benmansour, A., Bennet, P., Bernoux-Manat, B., Berthet, E., Berthoux, E., Bertolini, E., Bigot, A., Bisson-Vaivre, A., Blaison, G., Bolla, G., Bonidan, O., Bonnet, C., Borie, R., Bossert, M., Boudou, L., Bouhour, F., Bouiller, K., Bouldoires, B., Boussoualim, K., Bouvard, E., Brondino, R., Buchlin, P., Cabantous, L., Cacoub, P., Cadiou, S., Carteni, M., Carbasse, A., Castel, B., Cathebras, P., Caumont, H., Celant, A., Chaigne, B., Chaillous, B., Champy, R., Charcot, A., Charles, P., Charlot-Lambrecht, I., Charpin, C., Chatelus, E., Chaudier, B., Chertok, P., Chevalier, X., Chevreau, M., Chotard, E., Chu Miow Lin, D., Clavel, G., Clavel-Osorio, C., Cohen, F., Cohen, G., Colette-Cedoz, M.-E., Collercandy, N., Colombey, A., Comarmond, C., Combe, B., Comparon, C., Constant, E., Coquerelle, P., Corli, J., Corre, C., Costedoat-Chalumeau, N., Couret, M., Courvoisier, N., Coury-Lucas, F., Coutarel, C., Coutier, F., Damade, R., Daver-Malaterre, L., Dehimat, S., Delahousse, M., Barrois-Delattre, E., Denarie, D., Deprouw, C., Dernis, E., Deroux, A., Desbarbieux, R., Descamps, E., Deslandre, C., Desmurs, M., Despaux, J., Desplats, M., Detree, F., Devauchelle-Pensec, V., Dhote, R., Dieude, P., Dieudonne, Y., Diot, E., Direz, G., Djeddi, D.-D., Douvier, S., Drouet, B., Drumez, E., Duc, C., Ducornet, A., Dufauret-Lombard, C., Duhamel, A., Dumaine, C., Dumel, A.-E., Dumoulin-Richez, C., Duquesne, A., Durand, G., Durandin-Truffinet, M., Duret, P.-M., Duval, M., Ebbo, M., Ebstein, E., Economu-Dubosc, A., Emilie, S., Euvrard, R., Evon, P., Fabre, S., Fagedet, D., Farhat, M., Fauconier, M., Fechtenbaum, J., Felten, R., Fernandes, F., Ferreira-Maldent, N., Feurer, E., Fichet, A., Flaisler, F., Florens, N., Foltz, V., Fontanges, E., Foret, J., Fougerousse, A.-C., Fouque-Aubert, A., Foutrier-Morello, C., Francois-Pradier, H., Frantzen, L., Fritz, P., Froissart, A., Fulpin, J., Fuzibet, P., Gaches, F., Gagneux-Lemoussu, L., Penhoat-Gahier, M., Galland, J., Gandjbakhch, F., Garnier, N., Garraud, T., Garrot, J.-F., Gastaldi, R., Gaud-Listrat, V., Gauthier-Prieur, M., Georgescu, D., Gerard, N., Gervais, E., Gibert, C., Gibert, E., Gill, G., Gillard, J., Gilson, M., Gimonnet, P., Giraudet-Le Quintrec, J.-S., Giraud-Morelet, A., Glace, B., Glanowski, C., Godeau, B., Gombert, B., Gonnet-Gracia, C., Goulenok, T., Goupille, P., Gourmelen, O., Govindaraju-Audouard, S., Grados, F., Grall-Lerosey, M., Grardel, B., Grasland, A., Grateau, G., Groza, M., Guillaud, C., Guillaume, S., Guillibert, C., Guillot, X., Guilpain, P., Gury, A., Guyot, M.-H., Hacquard-Bouder, C., Havard, M.-N., Hellier, J.-P., Hennequin, P., Henriot, B., Henry, J., Hentgen, V., Hermet, M., Herasse, M., Hernandez, J., Hie, M., Hilliquin, P., Hinschberger, O., Hittinger-Roux, A., Holubar, J., Hudry, C., Huguenel, S., Jaccard, C., Jacquemier, J.-M., Jamard, B., Jan, C., Jean, S., Jouvray, M., Juge, P.-A., Juillard, L., Jullien, D., Kabala, A., Kabchou, A., Karkowski, L., Karman, F., Kemiche, F., Keraen, J., Kieffer, P., Kone-Paut, I., Koreichi, A., Kostine, M., La Batide Alanore, S., Lafforgue, P., Lahalle, S., Lambert, M., Lambrecht, I., Lanot, S., Lanteri, A., Larbre, J.-P., Latourte, A., Lavigne, C., Le Guen Guegan, S., Le Guenno, G., Leguy, D., Lebrun, A., Ledoult, E., Legoupil, N., Legrand, E., Lejeune, C., Leloire, O., Leroux, C., Leroy, R., Leroy-Gouix, M., Leturcq, T., Leurs, A., Leveque-Michaud, C., Limbach, F.-X., Liote, F., Lohse, A., Lozac'h, P., Lucas, V., Madelon, A., Magy-Bertrand, N., Mahevas, M., Maillard, H., Maillet, T., Malochet-Guinamand, S., Mangon, Q., Marchou-Lopez, S., Margarit, N., Marhadour, T., Mariette, X., Martin, C., Mathian, A., Maurier, F., Maury, F., Mazet-Guillaume, B., Mazouyez, A., Mazyad, H., Mehsen-Cetre, N., Meinzer, U., Melki, I., Messer, L., Miceli, C., Michaud, M., Michel, C., Michel, M., Michon, M., Milesi-Lecat, A.-M., Molto, A., Moly, M., Moranne, O., Morel, G., Morel, H., Morel, J., Morin, F., Moulinier, L., Moulis, G., Moura, B., Nguyen, M., Nicolas-Vullierme, S., Nielly, H., Nocturne, G., Nottez, A., Ollagnon, H.-O., Pacaud-Vitoux, I., Pagnier, A., Paris, C., Parrot, A., Pascart, T., Pascaud-Mansour, Y., Paulin, L., Pavy, S., Perard, L., Pers, Y.-M., Pha, M., Pichon, M., Pierreisnard, A., Pizana, G., Poignant, S., Poix, E., Portier, A., Poulet, A., Plassard, S., Pugnet, G., Puyraimond-Zemmour, D., Quartier-Dit-Maire, P., Quenet, M., Queyrel, V., Raffray, L., Remy, P., Renard, M., Rene, J., Revuz, S., Rey, B., Richard-Colmant, G., Riviere, E., Riviere, S., Robin, S., Rohmer, J., Roitg, I., Romier, M., Rolland, M., Roriz, M., Rosenberg, C., Rossi, L., Roth, O., Rouidi, S.-A., Roumier, M., Rousiere, M., Rousselin, C., Rouviere, B., Roux, C., Roux, F., Roux, M., Roux, N., Rouzaud, D., Rozenberg, S., Sacco, I., Sadji, F., Sailler, L., Salliot, C., Salmon, J.-H., Saraux, A., Schmidt, J., Seguier, J., Sellam, J., Senbel, E., Sene, T., Senet, P., Seve, P., Sicaud, A., Smets, P., Sobanski, V., Sordet, C., Sornay-Rendu, E., Souchaud-Debouverie, O., Sparsa, L., Spielmann, L., Steib, S., Stavris, C., Straus, C., Strotz, V., Szafors, P., Taffignon-Clave, S., Simoens, J., Theillac, C., Tenenbaum, N., Thomachot, B., Tieulie, N., Tiriau, S., Tison, A., Toussirot, E., Trefond, L., Trijau, S., Trouillier, S., Trouvin, A.-P., Truchetet, M.-E., Ulrich, M., Vaquier, J., Veillard, E., Veillon, L., Veillard, E., Veillon, L., Vial, G., Viallard, J.-F., Victor, J., Vidon, C., Vidon, M., Vigne, C., Virone, A., Warzocha, U., Wendling, D., Werle, C., Wibaux, C., Willems, A., Wisniewski, M., Woessner, J., & Xerri-Campano, B.
- Venue
- The Lancet Rheumatology
- Publisher
- Elsevier BV
- Published
- 2021-06
- Volume
- 3
- Issue
- 6
- Pages
- e419-e426
- ISSN
- 2665-9913 (ISSN-L)
- OpenAlex
- W3144879873
- Cited by
- 273
- References
- 25
- FWCI
- 18.51
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study. https://app.cochat.ai/papers/10.1016/s2665-9913(21)00059-x
- The paper
- Avouac, J., Drumez, E., Hachulla, E., Seror, R., Georgin-Lavialle, S., El Mahou, S., Pertuiset, E., Pham, T., Marotte, H., Servettaz, A., Domont, F., Chazerain, P., Devaux, M., Claudepierre, P., Langlois, V., Mekinian, A., Maria, A. T. J., Banneville, B., Fautrel, B., . . . Xerri-Campano, B. (2021). COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study. The Lancet Rheumatology. https://doi.org/10.1016/s2665-9913(21)00059-x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.